Verona Pharma (VRNA) Stock Price, News & Analysis

Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $72.15 to $75.47
• 50-Day Range: $53.90 to $74.73
• 52-Week Range: $11.39 to $75.47
• Volume: 1.61 million shs
• Average Volume: 1.30 million shs
• Market Capitalization: $6.06 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $81.50
• Consensus Rating: Buy

Verona Pharma Stock Analysis - MarketRank™

Verona Pharma scored higher than 38% of companies evaluated by MarketBeat, and ranked 471st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Buy

Consensus Rating

Verona Pharma has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Verona Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Verona Pharma are expected to grow in the coming year, from ($1.95) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Verona Pharma is -38.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Verona Pharma is -38.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Verona Pharma has a P/B Ratio of 24.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.87% of the outstanding shares of Verona Pharma have been sold short.

Short Interest Ratio / Days to Cover

Verona Pharma has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Verona Pharma has recently increased by 2.83%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verona Pharma does not currently pay a dividend.

Dividend Growth

Verona Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.87% of the outstanding shares of Verona Pharma have been sold short.

Short Interest Ratio / Days to Cover

Verona Pharma has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Verona Pharma has recently increased by 2.83%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.50

News Sentiment

Verona Pharma has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Verona Pharma this week, compared to 7 articles on an average week.

Search Interest

12 people have searched for VRNA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

6 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,208,741.00 in company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Verona Pharma is held by insiders.

Percentage Held by Institutions

85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VRNA Stock Analysis - Frequently Asked Questions

How have VRNA shares performed this year?

Verona Pharma's stock was trading at $46.44 at the start of the year. Since then, VRNA stock has increased by 60.9% and is now trading at $74.73.
View the best growth stocks for 2025 here.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings data on Tuesday, April, 29th. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The company had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million.
Read the conference call transcript.

When did Verona Pharma IPO?

Verona Pharma (VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are Verona Pharma's major shareholders?

Top institutional investors of Verona Pharma include Frazier Life Sciences Management L.P. (4.26%), Eventide Asset Management LLC (3.57%), Wellington Management Group LLP (2.63%) and Price T Rowe Associates Inc. MD (2.30%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Andrew Fisher, Martin Edwards and Vikas Sinha.
View institutional ownership trends.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 5/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRNA
• CIK: 1657312
• Web: www.veronapharma.com
• Phone: 011-44-0-2032834200
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $81.50
• High Stock Price Target: $107.00
• Low Stock Price Target: $57.00
• Potential Upside/Downside: +9.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-54,370,000.00
• Net Margins: N/A
• Pretax Margin: -2,698.40%
• Return on Equity: -79.54%
• Return on Assets: -43.49%

Debt

• Debt-to-Equity Ratio: 0.93
• Current Ratio: 13.03
• Quick Ratio: 12.88

Sales & Book Value

• Annual Sales: $118.54 million
• Price / Sales: 51.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 24.11

Miscellaneous

• Outstanding Shares: 81,080,000
• Free Float: 76,103,000
• Market Cap: $6.06 billion
• Optionable: Optionable
• Beta: 0.20